NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) and Carisma Therapeutics (NASDAQ:CARM – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and price targets for NewAmsterdam Pharma and Carisma Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
| Carisma Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
NewAmsterdam Pharma currently has a consensus target price of $49.00, suggesting a potential upside of 57.81%. Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 17,443.86%. Given Carisma Therapeutics’ higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than NewAmsterdam Pharma.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NewAmsterdam Pharma | $22.50 million | 161.32 | -$203.82 million | ($1.79) | -17.35 |
| Carisma Therapeutics | $10.77 million | 0.02 | -$60.48 million | $0.73 | 0.01 |
Carisma Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of -9.34, suggesting that its share price is 1,034% less volatile than the S&P 500.
Profitability
This table compares NewAmsterdam Pharma and Carisma Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NewAmsterdam Pharma | -943.23% | -26.49% | -24.37% |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
Institutional and Insider Ownership
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
NewAmsterdam Pharma beats Carisma Therapeutics on 9 of the 15 factors compared between the two stocks.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
